Seventy-five patients with gastric carcinoma underwent preoperative staging with computed tomography (CT). In 14 patients, CT failed to demonstrate lymphadenopathy despite the presence of malignant lymph nodes at surgery. In 13 patients, CT demonstrated enlarged nodes, but no malignant involvement was found at surgery. Although spread to the pancreas was correctly predicted in three patients with lack of fat plane between tumor and pancreas, five patients lacking a fat plane had no invasion, whereas eight patients with an intact fat plane had invasion. Thirty-five patients (47%) were incorrectly staged with CT:23 (31%) were understaged and 12 (16%) were overstaged. CT does not accurately display the true extent of disease in patients with gastric carcinoma and therefore should not be used routinely for staging.
Two hundred abdominal computed tomographic (CT) scans in 200 patients, 100 performed with low osmolality contrast (ioversol 68%, 100 ml) and 100 performed with high osmolality contrast (diatrizoate meglumine 60%, 150 ml), were retrospectively evaluated for the presence of renal streak artifact. Contrast was administered by hand injection at a rate of approximately 1-2 ml/s and sequential scanning was employed. Of the scans performed with high osmolality contrast, 70% had no artifact, 28% had minimal artifact, and only 2% had marked artifact. Only 26% of the exams performed with low osmolality contrast were artifact-free, whereas 53% demonstrated minimal artifact and 21% demonstrated marked artifact. The likelihood of encountering renal streak artifact when using low osmolality contrast agents is almost seven times greater than when high osmolality contrast agents are used.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.